This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1988 Sep;7(3):289-90.

doi: 10.1016/0167-6296(88)90030-6.

A QALY is a QALY--or is it?

PMID: 10291478
DOI: 10.1016/0167-6296(88)90030-6

A QALY is a QALY--or is it?

M C Weinstein. J Health Econ. 1988 Sep.

. 1988 Sep;7(3):289-90.

doi: 10.1016/0167-6296(88)90030-6.

Author

PMID: 10291478
DOI: 10.1016/0167-6296(88)90030-6

No abstract available

PubMed Disclaimer

Similar articles

Should QALYs be programme-specific?
Donaldson C, Atkinson A, Bond J, Wright K. Donaldson C, et al. J Health Econ. 1988 Sep;7(3):239-57. doi: 10.1016/0167-6296(88)90027-6. J Health Econ. 1988. PMID: 10312836
Allocating resources to health care: is the QALY (Quality Adjusted Life Year) a technical solution to a political problem?
Carr-Hill RA. Carr-Hill RA. Int J Health Serv. 1991;21(2):351-63. doi: 10.2190/HPLM-EGXV-BWKY-5XBN. Int J Health Serv. 1991. PMID: 2071312
Placing a value on life and limb: the role of the informed consumer.
Eastaugh SR. Eastaugh SR. Health Matrix. 1983 Winter;1(1):5-21. Health Matrix. 1983. PMID: 10310247 Review.
Measuring the benefits and costs of medical care: the contribution of health status measurement.
Hurst JW. Hurst JW. Health Trends. 1984 Feb;16(1):16-9. Health Trends. 1984. PMID: 10310435 No abstract available.
The significance of contextual factors in valuing health states.
Nord E. Nord E. Health Policy. 1989;13(3):189-98. doi: 10.1016/0168-8510(89)90092-4. Health Policy. 1989. PMID: 10304223 Review.

See all similar articles

Cited by

The Value of Medicines: A Crucial but Vague Concept.
Antoñanzas F, Terkola R, Postma M. Antoñanzas F, et al. Pharmacoeconomics. 2016 Dec;34(12):1227-1239. doi: 10.1007/s40273-016-0434-8. Pharmacoeconomics. 2016. PMID: 27444306 Review.
Ethical Hurdles in the Prioritization of Oncology Care.
de Groot F, Capri S, Castanier JC, Cunningham D, Flamion B, Flume M, Herholz H, Levin LÅ, Solà-Morales O, Rupprecht CJ, Shalet N, Walker A, Wong O. de Groot F, et al. Appl Health Econ Health Policy. 2017 Apr;15(2):119-126. doi: 10.1007/s40258-016-0288-4. Appl Health Econ Health Policy. 2017. PMID: 27766548 Free PMC article.
Fair Funding Decisions: Consistency of the Time Horizons Used in the Calculation of Quality-Adjusted Life Years for Therapies for Very Rare Diseases by the National Institute for Health and Care Excellence in England.
Barman-Aksözen J, Hentschel N, Pettersson M, Schupp E, Granata F, Dechant C, Aksözen MH, Falchetto R. Barman-Aksözen J, et al. Int J Environ Res Public Health. 2024 May 13;21(5):616. doi: 10.3390/ijerph21050616. Int J Environ Res Public Health. 2024. PMID: 38791830 Free PMC article.
Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US.
Bridges JF, Onukwugha E, Mullins CD. Bridges JF, et al. Pharmacoeconomics. 2010;28(3):175-84. doi: 10.2165/11530650-000000000-00000. Pharmacoeconomics. 2010. PMID: 20067332
On individual preferences and aggregation in economic evaluation in healthcare.
Liljas B, Lindgren B. Liljas B, et al. Pharmacoeconomics. 2001;19(4):323-35. doi: 10.2165/00019053-200119040-00001. Pharmacoeconomics. 2001. PMID: 11383750 Review.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science